Samsungbioepis Co,.Ltd
Samsung Bioepis Co., Ltd., a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative approach in the biosimilars industry. Founded in 2012, the company has rapidly established itself as a key player in the global market, focusing on the development and commercialisation of high-quality biosimilars and biologics. With a strong presence in major operational regions including North America, Europe, and Asia, Samsung Bioepis offers a diverse portfolio of products that includes biosimilars for oncology and autoimmune diseases. Their commitment to rigorous research and development, combined with advanced manufacturing capabilities, sets them apart in a competitive landscape. Notable achievements include strategic partnerships with global pharmaceutical leaders, enhancing their market position and expanding access to affordable treatments. Samsung Bioepis continues to drive innovation, making significant contributions to the healthcare sector.
DitchCarbon Score
How does Samsungbioepis Co,.Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsungbioepis Co,.Ltd's score of 33 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsungbioepis Co,.Ltd's reported carbon emissions
In 2023, Samsung Bioepis Co., Ltd reported total carbon emissions of approximately 6,295,405 kg CO2e, comprising about 1,209,479 kg CO2e from Scope 1 and about 5,085,926 kg CO2e from Scope 2 emissions. This represents a slight increase from 2022, where emissions were around 6,200,000 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, achieving a notable decrease in total emissions from 2021, which recorded approximately 6,851,000 kg CO2e, and from 2020, which was about 6,729,000 kg CO2e. This trend indicates a proactive approach to managing emissions, particularly in Scope 1 and Scope 2 categories, which are directly linked to their operational activities and energy consumption. Despite the absence of specific reduction targets or initiatives disclosed, Samsung Bioepis continues to focus on sustainability as part of its corporate strategy. The company’s emissions intensity has shown improvement, with a GHG intensity of 0.0062 in 2023, down from 0.0064 in 2022, reflecting ongoing efforts to enhance efficiency relative to revenue. Overall, Samsung Bioepis is actively working towards minimising its environmental impact, aligning with industry standards for climate action and sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,433,412 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,296,110 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsungbioepis Co,.Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
